Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Posted by George Bondi on Aug 26th, 2026

Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 316,392 shares, a decline of 79.9% from the July 30th total of 1,577,365 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average daily volume of 2,216,181 shares, the days-to-cover ratio is currently 0.1 days.

Moleculin Biotech Price Performance

Shares of NASDAQ:MBRX traded down $0.01 during midday trading on Wednesday, reaching $0.60. 381,178 shares of the company’s stock were exchanged, compared to its average volume of 578,195. The stock has a market cap of $11.76 million, a price-to-earnings ratio of -0.08 and a beta of 1.83. Moleculin Biotech has a fifty-two week low of $0.16 and a fifty-two week high of $15.75. The firm’s 50 day simple moving average is $1.75 and its two-hundred day simple moving average is $2.30.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.15. Equities research analysts predict that Moleculin Biotech will post -3.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MBRX shares. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $22.00.

Read Our Latest Research Report on MBRX

Institutional Trading of Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. Institutional investors and hedge funds own 15.52% of the company’s stock.

About Moleculin Biotech

(Get Free Report)

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.